Its lead drug candidate, selinexor (KPT-330), is an XPO1 inhibitor being evaluated in multiple late stage clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies.

Other drug candidates in development include oral verdinexor (KPT-335) as an anti-viral agent, as well as a treatment for cancer in companion dogs and oral KPT-350 as a treatment for neurological, inflammatory and autoimmune conditions.